keyword
MENU ▼
Read by QxMD icon Read
search

Ldx

keyword
https://www.readbyqxmd.com/read/29028590/efficacy-and-tolerability-of-lisdexamfetamine-as-an-antidepressant-augmentation-strategy-a-meta-analysis-of-randomized-controlled-trials
#1
Peter Giacobbe, Uros Rakita, Raymond Lam, Roumen Milev, Sidney H Kennedy, Roger S McIntyre
BACKGROUND: Psychostimulants have been used in the treatment of depression, with mixed results. This meta-analysis examines the efficacy and tolerability of the stimulant Lisdexamfetamine (LDX) as an add-on strategy in those with MDD who have failed to respond to an antidepressant. METHOD: Randomized control trials were identified and extracted from Pubmed; Web of Science; PsychINFO; and Cochrane Library. The efficacy of LDX was evaluated using Hedges' g and Odds Ratio, whereas Risk Difference was used to assess the safety and tolerability of LDX...
October 3, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28980198/randomized-double-blind-placebo-controlled-acute-comparator-trials-of-lisdexamfetamine-and-extended-release-methylphenidate-in-adolescents-with-attention-deficit-hyperactivity-disorder
#2
Jeffrey H Newcorn, Peter Nagy, Ann C Childress, Glen Frick, Brian Yan, Steven Pliszka
BACKGROUND: Psychostimulants are considered first-line pharmacotherapy for youth with attention-deficit/hyperactivity disorder (ADHD), but questions remain regarding the comparative efficacy of amphetamine- and methylphenidate-based agents. OBJECTIVE: Our objective was to describe two acute randomized, double-blind, placebo-controlled, head-to-head studies of lisdexamfetamine dimesylate (LDX) and osmotic-release oral system methylphenidate (OROS-MPH) in adolescents with ADHD...
October 4, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28855799/review-of-lisdexamfetamine-dimesylate-in-adults-with-attention-deficit-hyperactivity-disorder
#3
REVIEW
Jadwiga Najib, Dexter Wimer, Julie Zeng, Kristina W Lam, Natalya Romanyak, Eva Paige Morgan, Anu Thadavila
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity disorder (ADHD) dosed once daily. Due to its long-acting properties, LDX remains pharmacologically inactive until an enzymatic process predominantly associated with red blood cells converts it to the active ingredient, d-amphetamine and the amino acid lysine. The efficacy of LDX over placebo has been demonstrated in several studies in adults with moderate to severe ADHD with significant improvements noted in ADHD rating scales, Clinical Global Improvement scores, and assessments of executive function, for all doses of LDX (30-70 mg daily)...
2017: Journal of Central Nervous System Disease
https://www.readbyqxmd.com/read/28667569/long-term-safety-and-efficacy-of-lisdexamfetamine-dimesylate-in-children-and-adolescents-with-adhd-a-phase-iv-2-year-open-label-study-in-europe
#4
David R Coghill, Tobias Banaschewski, Peter Nagy, Isabel Hernández Otero, César Soutullo, Brian Yan, Beatriz Caballero, Alessandro Zuddas
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is increasingly recognized as a persistent disorder requiring long-term management. OBJECTIVES: Our objective was to evaluate the 2-year safety and efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents with ADHD. METHODS: Participants (aged 6-17 years) with ADHD received open-label, dose-optimized LDX 30, 50, or 70 mg/day for 104 weeks. Safety monitoring included treatment-emergent adverse events (TEAEs), vital signs, electrocardiography, and growth...
July 2017: CNS Drugs
https://www.readbyqxmd.com/read/28513760/cell-therapy-in-the-treatment-of-bipolar-mania-in-an-animal-model-a-proof-of-concept-study
#5
Bruna M Ascoli, Rafael Colombo, Luiza P Géa, Paula B Terraciano, Sabrina B Pizzato, Fernanda S de Oliveira, Elizabeth Cirne-Lima, Flávio Kapczinski, Adriane R Rosa
INTRODUCTION: The rationale of mesenchymal stem cells (MSCs) as a novel therapeutic approach in certain neurodegenerative diseases is based on their ability to promote neurogenesis. Hippocampal atrophy has been related to bipolar disorder (BD) in preclinical, imaging and postmortem studies. Therefore, the development of new strategies to stimulate the neurogenesis process in BD is crucial. OBJECTIVES: To investigate the behavioral and neurochemical changes induced by transplantation of MSCs in a model of mania-like behavior induced by lisdexamfetamine dimesylate (LDX)...
July 2017: Trends in Psychiatry and Psychotherapy
https://www.readbyqxmd.com/read/28481434/time-course-of-the-effects-of-lisdexamfetamine-dimesylate-in-two-phase-3-randomized-double-blind-placebo-controlled-trials-in-adults-with-binge-eating-disorder
#6
Susan L McElroy, James I Hudson, Maria Gasior, Barry K Herman, Jana Radewonuk, Denise Wilfley, Joan Busner
OBJECTIVE: This study examined the time course of efficacy-related endpoints for lisdexamfetamine dimesylate (LDX) versus placebo in adults with protocol-defined moderate to severe binge-eating disorder (BED). METHODS: In two 12-week, double-blind, placebo-controlled studies, adults meeting DSM-IV-TR BED criteria were randomized 1:1 to receive placebo or dose-optimized LDX (50 or 70 mg). Analyses across visits used mixed-effects models for repeated measures (binge eating days/week, binge eating episodes/week, Yale-Brown Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE] scores, percentage body weight change) and chi-square tests (Clinical Global Impressions-Improvement [CGI-I; from the perspective of BED symptoms] scale dichotomized as improved or not improved)...
August 2017: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/28383364/a-phase-3-multicenter-open-label-12-month-extension-safety-and-tolerability-trial-of-lisdexamfetamine-dimesylate-in-adults-with-binge-eating-disorder
#7
MULTICENTER STUDY
Maria Gasior, James Hudson, Javier Quintero, M Celeste Ferreira-Cornwell, Jana Radewonuk, Susan L McElroy
BACKGROUND: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). METHODS: Adults (aged 18-55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label extension study (dose optimization, 4 weeks [initial titration dose, 30-mg LDX; target doses, 50- or 70-mg LDX]; dose maintenance, 48 weeks). Safety evaluations included the occurrence of treatment-emergent adverse events (TEAEs), vital sign and weight assessments, and Columbia-Suicide Severity Rating Scale responses...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28258319/comparative-efficacy-and-safety-of-attention-deficit-hyperactivity-disorder-pharmacotherapies-including-guanfacine-extended-release-a-mixed-treatment-comparison
#8
REVIEW
Alain Joseph, Rajeev Ayyagari, Meng Xie, Sean Cai, Jipan Xie, Michael Huss, Vanja Sikirica
This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6-17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among children and adolescents with ADHD. A Bayesian network meta-analysis was conducted to compare change in symptoms using the ADHD Rating Scale Version IV (ADHD-RS-IV), Clinical Global Impression-Improvement (CGI-I) response, all-cause discontinuation, and adverse event-related discontinuation...
August 2017: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/28129639/ladarixin-a-dual-cxcr1-2-inhibitor-attenuates-experimental-melanomas-harboring-different-molecular-defects-by-affecting-malignant-cells-and-tumor-microenvironment
#9
Daria Marley Kemp, Alyson Pidich, Mary Larijani, Rebecca Jonas, Elizabeth Lash, Takami Sato, Mizue Terai, Maria De Pizzol, Marcello Allegretti, Olga Igoucheva, Vitali Alexeev
CXCR1 and CXCR2 chemokine receptors and their ligands (CXCL1/2/3/7/8) play an important role in tumor progression. Tested to date CXCR1/2 antagonists and chemokine-targeted antibodies were reported to affect malignant cells in vitro and in animal models. Yet, redundancy of chemotactic signals and toxicity hinder further clinical development of these approaches. In this pre-clinical study we investigated the capacity of a novel small molecule dual CXCR1/2 inhibitor, Ladarixin (LDX), to attenuate progression of experimental human melanomas...
February 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28093662/a-cost-effectiveness-analysis-of-lisdexamfetamine-dimesylate-in-the-treatment-of-adults-with-attention-deficit-hyperactivity-disorder-in-the-uk
#10
Evelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, Josephine A Mauskopf
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder in children that may persist into adulthood. Lisdexamfetamine dimesylate (LDX) is approved in many countries for ADHD treatment in children, adolescents, and adults. OBJECTIVES: Estimate the cost-effectiveness of LDX as a first- or second-line treatment for adults with ADHD from the United Kingdom (UK) National Health Service (NHS) perspective compared with methylphenidate extended release (MPH-ER) and atomoxetine (ATX)...
January 16, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27935735/pharmacokinetic-and-pharmacodynamic-properties-of-lisdexamfetamine-in-adults-with-attention-deficit-hyperactivity-disorder
#11
Lenard A Adler, Samuel Alperin, Terry Leon, Stephen V Faraone
BACKGROUND: Lisdexamfetamine (LDX) is a prodrug and consists of an active moiety, d-amphetamine, bound to lysine. Clinically, d-amphetamine becomes available postcleavage of the prodrug in the blood stream. Clinical effects of LDX in attention-deficit/hyperactivity disorder (ADHD) have been shown to persist up to 14 hours; however, pharmacokinetic (PK) data of LDX and amphetamine in ADHD adults are not currently available. OBJECTIVES: (1) To examine PK data of LDX and d-amphetamine in plasma and (2) to compare such PK data with Time-Sensitive ADHD Symptom Scale (TASS) ratings (PK vs...
March 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/27842942/evaluation-of-50-khz-ultrasonic-vocalizations-in-animal-models-of-mania-ketamine-and-lisdexamfetamine-induced-hyperlocomotion-in-rats
#12
Etieli Wendler, Camila Pasquini de Souza, Debora Dalla Vecchia, Luiz Kae Sales Kanazawa, Palloma de Almeida Soares Hocayen, Markus Wöhr, Rainer K W Schwarting, Roberto Andreatini
Drug-induced hyperlocomotion in rodents is frequently used as a behavioral model for mania. However, the use of locomotor activity as the single parameter in these animal models of mania may pose some limitations for developing new pharmacological treatments. Thus, alternative behavioral markers are required. Fifty-kHz ultrasonic vocalizations (USV), which are thought to represent positive affect, are increased by the administration of the psychostimulant d-amphetamine, an effect that can be prevented by lithium treatment, the gold standard antimanic drug for treating bipolar disorder...
December 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27759913/accurate-mr-thermometry-by-hyperpolarized-129-xe
#13
Le Zhang, Alex Burant, Andrew McCallister, Victor Zhao, Karl M Koshlap, Simone Degan, Michael Antonacci, Rosa Tamara Branca
PURPOSE: To investigate the temperature dependence of the resonance frequency of lipid-dissolved xenon (LDX) and to assess the accuracy of LDX-based MR thermometry. METHODS: The chemical shift temperature dependence of water protons, methylene protons, and LDX was measured from samples containing tissues with varying fat contents using a high-resolution NMR spectrometer. LDX results were then used to acquire relative and absolute temperature maps in vivo and the results were compared with PRF-based MR thermometry...
September 2017: Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine
https://www.readbyqxmd.com/read/27738872/an-evaluation-on-the-efficacy-and-safety-of-treatments-for-attention-deficit-hyperactivity-disorder-in-children-and-adolescents-a-comparison-of-multiple-treatments
#14
Ying Li, Jie Gao, Shu He, Yan Zhang, Qiwei Wang
Attention deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioral disorders. We carried out this comparison of multiple treatments based on sufficient data in attempt to evaluate the efficacy and safety of ADHD medication for children and adolescents. PubMed, Embase and the Cochrane Database were used to search for relevant articles. Changes in the ADHD Rating Scale (ADHD-RS) scores and the Conners' Parent Rating Scale-Revised (CPRS) scores were used as outcomes for efficacy. Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications...
October 13, 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/27661399/relative-bioavailabilities-of-lisdexamfetamine-dimesylate-and-d-amphetamine-in-healthy-adults-in-an-open-label-randomized-crossover-study-after-mixing-lisdexamfetamine-dimesylate-with-food-or-drink
#15
James Ermer, Mary Corcoran, Kenneth Lasseter, Patrick T Martin
BACKGROUND: This open-label, crossover study examined lisdexamfetamine dimesylate (LDX) and D-amphetamine pharmacokinetics in healthy adults after administration of an intact LDX capsule or after the capsule was emptied into orange juice or yogurt and the contents consumed. METHODS: Healthy adult volunteers (N = 30) were administered a 70-mg LDX capsule or the contents of a 70-mg capsule mixed with yogurt or orange juice using a 3-way crossover design. Blood samples were collected serially for up to 96 hours after dose...
December 2016: Therapeutic Drug Monitoring
https://www.readbyqxmd.com/read/27650406/lisdexamfetamine-dimesylate-in-binge-eating-disorder-a-placebo-controlled-trial
#16
Anna I Guerdjikova, Nicole Mori, Thomas J Blom, Paul E Keck, Stephanie L Williams, Jeffrey A Welge, Susan L McElroy
OBJECTIVE: To evaluate lisdexamfetamine dimesylate (LDX) in the treatment of binge eating disorder (BED). METHOD: Fifty participants with BED received LDX (20-70 mg/day) (n = 25) or placebo (n = 25) for up to 12 weeks in a single-center, randomized, double-blind, and flexible-dose trial. The primary outcome measure was binge eating (BE) days/week. RESULTS: In the primary longitudinal analysis, compared with placebo, LDX was not associated with a significantly greater rate of reduction in BE days/week, as well as BE episodes/week, and scores on the Clinical Global Impression-Severity or Yale-Brown Obsessive-Compulsive Scale modified for binge eating scales...
September 2016: Human Psychopharmacology
https://www.readbyqxmd.com/read/27598968/longitudinal-magnetic-resonance-imaging-reveals-striatal-hypertrophy-in-a-rat-model-of-long-term-stimulant-treatment
#17
D Biezonski, R Shah, A Krivko, J Cha, D N Guilfoyle, J Hrabe, S Gerum, S Xie, Y Duan, R Bansal, B L Leventhal, B S Peterson, C Kellendonk, J Posner
Stimulant treatment is highly effective in mitigating symptoms associated with attention-deficit/hyperactivity disorder (ADHD), though the neurobiological underpinnings of this effect have not been established. Studies using anatomical magnetic resonance imaging (MRI) in children with ADHD have suggested that long-term stimulant treatment may improve symptoms of ADHD in part by stimulating striatal hypertrophy. This conclusion is limited, however, as these studies have either used cross-sectional sampling or did not assess the impact of treatment length on their dependent measures...
September 6, 2016: Translational Psychiatry
https://www.readbyqxmd.com/read/27550732/lisdexamfetamine-effects-on-executive-activation-and-neurochemistry-in-menopausal-women-with-executive-function-difficulties
#18
Sheila Shanmugan, James Loughead, Ravi Prakash Reddy Nanga, Mark Elliott, Hari Hariharan, Dina Appleby, Deborah Kim, Kosha Ruparel, Ravinder Reddy, Thomas E Brown, C Neill Epperson
Many women with no history of executive dysfunction report difficulties in this domain during the menopause transition. Lisdexamfetamine (LDX) has been suggested to be a safe and effective treatment option for these women. However, the mechanism by which LDX improves executive functioning in these women is not known. Here we investigated the effects of LDX on brain activation and neurochemistry, hypothesizing that LDX would be associated with increased activation and decreased glutamate in executive regions...
January 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27530525/a-cost-utility-analysis-of-lisdexamfetamine-versus-atomoxetine-in-the-treatment-of-children-and-adolescents-with-attention-deficit-hyperactivity-disorder-and-inadequate-response-to-methylphenidate
#19
Evelina A Zimovetz, Stephen M Beard, Paul Hodgkins, Matthias Bischof, Josephine A Mauskopf, Juliana Setyawan
BACKGROUND: An economic analysis from the perspective of the UK National Health Service (NHS) evaluated the cost effectiveness of lisdexamfetamine dimesylate (LDX) compared with atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder who have had an inadequate response to methylphenidate. METHODS: A 1-year decision-analytic model was constructed, with the health outcomes "response", "nonresponse", and "unable to tolerate". Clinical data were taken from a head-to-head, randomized controlled trial in inadequate responders to methylphenidate...
October 2016: CNS Drugs
https://www.readbyqxmd.com/read/27518755/method-validation-and-determination-of-lisdexamfetamine-and-amphetamine-in-oral-fluid-plasma-and-urine-by-lc-ms-ms
#20
Eloisa Comiran, Fabiano Barreto, Leonardo Z Meneghini, Graciela Carlos, Pedro E Fröehlich, Renata Pereira Limberger
Lisdexamfetamine (LDX) is a long-acting prodrug stimulant indicated for the treatment of attention-deficit/hyperactivity disorder and binge-eating disorder symptoms. In vivo hydrolysis of LDX amide bond releases the therapeutically active d-amphetamine (d-AMPH). Since toxicological tests in biological samples can detect AMPH from the use of some legal medications, efficient methods are needed in order to correctly interpret the results. The aim of this study was to develop and validate an LC-MS/MS method for the simultaneous quantification of LDX and its main biotransformation product AMPH in human oral fluid, plasma and urine...
March 2017: Biomedical Chromatography: BMC
keyword
keyword
21686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"